×
Synlogic Share Holder Equity 2013-2025 | SYBX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Synlogic share holder equity from 2013 to 2025. Share holder equity can be defined as the sum of preferred and common equity items
View More
Synlogic Share Holder Equity 2013-2025 | SYBX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Synlogic share holder equity from 2013 to 2025. Share holder equity can be defined as the sum of preferred and common equity items
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$220.6B
Amgen (AMGN)
$158.8B
Gilead Sciences (GILD)
$136.4B
Vertex Pharmaceuticals (VRTX)
$120.4B
Bristol Myers Squibb (BMY)
$95.4B
GSK (GSK)
$78.4B
CSL (CSLLY)
$76.6B
Regeneron Pharmaceuticals (REGN)
$61.3B
Alnylam Pharmaceuticals (ALNY)
$41.1B
Argenex SE (ARGX)
$34.3B
BioNTech SE (BNTX)
$27.1B
Royalty Pharma (RPRX)
$20.2B
Biogen (BIIB)
$19.7B
Insmed (INSM)
$18.6B
Illumina (ILMN)
$15.7B
Genmab (GNMSF)
$14.2B
Genmab (GMAB)
$13.7B
Incyte (INCY)
$13.3B
Moderna (MRNA)
$13B
Exelixis (EXEL)
$12.2B
BioMarin Pharmaceutical (BMRN)
$11.1B
QIAGEN (QGEN)
$10.7B
Ascendis Pharma (ASND)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.4B
Exact Sciences (EXAS)
$9.8B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Bio-Techne Corp (TECH)
$8.5B
Blueprint Medicines (BPMC)
$8.4B
Roivant Sciences (ROIV)
$7.7B
Repligen (RGEN)
$7.3B